Bipartisan Arizona lawmakers have filed a bill to promote research into the medical potential of psilocybin mushrooms for a variety of conditions that could inform future reforms on authorizing psychedelic-assisted therapy.
The legislation from Reps. Kevin Payne (R), Jennifer Longdon (D), Stacey Travers (D) and Sen. T. J. Shope (R) is one of the latest examples of how lawmakers across the aisle are approaching psychedelics policy in the 2023 session, which has already seen the issue addressed in more than a dozen bills in state legislatures across the country.
This proposal is focused on psilocybin research, providing $30 million in grants over the course of three years for scientists to study the impact of the psychedelic on 13 different conditions such as post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms and substance misuse disorder.
It wouldn’t legalize psilocybin like lawmakers in several other states are aiming to accomplish, but the research that the bill would support is meant to steer the conversation about broader reforms down the line.
The research grants would be appropriated for phase I, II and III clinical trials that are “capable of being approved by the United States Food and Drug Administration (FDA) to evaluate
Read full article on Marijuana Moment
